Volume 152, Issue 1, Pages 300-301 (January 2017) Sofosbuvir and Daclatasvir Anti–Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient Mhairi C. Donnelly Gastroenterology Volume 152, Issue 1, Pages 300-301 (January 2017) DOI: 10.1053/j.gastro.2016.05.060 Copyright © 2017 AGA Institute Terms and Conditions
Figure 1 (A) Trend on hepatitis E virus RNA and hepatitis C virus PCR during sofosbuvir and daclatasvir therapy. (B) Change in percentage of CD4+ naïve cells, central memory (TCM) cells, effector memory (TEM) cells and terminal effector (TTE) cells pre- and during sofosbuvir and daclatasvir therapy. (C) Change in percentage of CD8+ naïve cells, central memory (TCM) cells, effector memory (TEM) cells and terminal effector (TTE) cells pre- and during sofosbuvir and daclatasvir therapy. Gastroenterology 2017 152, 300-301DOI: (10.1053/j.gastro.2016.05.060) Copyright © 2017 AGA Institute Terms and Conditions